Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis


Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.

Aim(s): The present work focuses on the efficacy and safety of Pazopanib in metastatic and locally advanced NEN patients (pts)

Materials and methods: A systematic search in major databases Medline/PubMed, Cochrane,Embase and in supplementary of principal international Meeting was performed.English language was defined as a restriction. Four authors independently conducted study selection and also assess risk of bias and extract study data. Four published clinical trials and 2 abstract were identified.One trial was excluded because of the topic and 1 abstract because of the lacking information in meeting resources.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Bongiovanni A, Liverani C, Recine f, Fausti V, Mercatali L,

Keywords: pazopanib, neuroendocrine neoplasia, neuroendocrine tumors, meta-analysis, carcinoid,

To read the full abstract, please log into your ENETS Member account.